Microglial activation in Alzheimer's disease: The role of flavonoids and microRNAs

• Published in: Journal of leukocyte biology Vol. 112; no. 1; pp. 47 - 77
• Main Authors: Medrano‐Jiménez, Elisa, Meza‐Sosa, Karla F., Urbán‐Aragón, José A., Secundino, Ismael, Pedraza‐Alva, Gustavo, Pérez‐Martínez, Leonor
• Format: Journal Article
• Language: English
• Published: United States 01.07.2022
• Subjects: microglial cells; miRNAs; neurodegenerative disease; neuroinflammation; neurodegenerative disease; miRNAs; microglial cells; neuroinflammation
• ISSN: 0741-5400; 1938-3673
• DOI: 10.1002/JLB.3MR1021-531R

Alzheimer's disease (AD) is the most common form of senile dementia and is characterized by progressive cognitive impairment and neuronal degeneration. Microglial activation is an important pathologic hallmark of AD. During disease progression, microglial cells switch from an alternative or anti‐inflammatory and neuroprotective profile (M2) to a classic or proinflammatory and neurotoxic profile (M1). Phenotypically, M1 microglia is characterized by the activation of inflammatory signaling pathways that cause increased expression of proinflammatory genes, including those coding for cytokines and chemokines. This microglia‐mediated neuroinflammation contributes to neuronal cell death. Recent studies in microglial cells have shown that a group of plant‐derived compounds, known as flavonoids, possess anti‐inflammatory properties and therefore exert a neuroprotective effect through regulating microglia activation. Here, we discuss how flavonoids can promote the switch from an inflammatory M1 phenotype to an anti‐inflammatory M2 phenotype in microglia and how this represents a valuable opportunity for the development of novel therapeutic strategies to blunt neuroinflammation and boost neuronal recovery in AD. We also review how certain flavonoids can inhibit neuroinflammation through their action on the expression of microglia‐specific microRNAs (miRNAs), which also constitute a key therapeutic approach in different neuropathologies involving an inflammatory component, including AD. Finally, we propose novel targets of microglia‐specific miRNAs that may be considered for AD treatment. Graphical Review of how flavonoids control microglial activation states through regulation of microRNAs and the implications in Alzheimer's disease appearance and progression.